{"name":"Innovative Medical","slug":"innovative-medical","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":2198000,"revenueGrowth":12.4,"grossMargin":0,"rdSpend":316000,"netIncome":-2399000,"cash":1058000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":15,"colorKey":"oncology","drugs":[{"name":"1. Optive","genericName":"1. Optive","slug":"1-optive","indication":"Other","status":"marketed"},{"name":"Dermatix Q","genericName":"Dermatix Q","slug":"dermatix-q","indication":"Other","status":"marketed"},{"name":"Bimatoprost 0.03%, Latanoprost","genericName":"Bimatoprost 0.03%, Latanoprost","slug":"bimatoprost-0-03-latanoprost","indication":"Other","status":"marketed"},{"name":"Brimonidine Purite 0.15%, Dorzolamide 2%, Latanoprost","genericName":"Brimonidine Purite 0.15%, Dorzolamide 2%, Latanoprost","slug":"brimonidine-purite-0-15-dorzolamide-2-latanoprost","indication":"Other","status":"marketed"},{"name":"FreshKote","genericName":"FreshKote","slug":"freshkote","indication":"Other","status":"marketed"},{"name":"Gatifloxacin 0.3%","genericName":"Gatifloxacin 0.3%","slug":"gatifloxacin-0-3","indication":"Other","status":"marketed"},{"name":"Ketorolac, Nepafenac","genericName":"Ketorolac, Nepafenac","slug":"ketorolac-nepafenac","indication":"Other","status":"marketed"},{"name":"Systane","genericName":"Systane","slug":"systane","indication":"Other","status":"marketed"},{"name":"0.15% sodium Hyaluronate","genericName":"0.15% sodium Hyaluronate","slug":"0-15-sodium-hyaluronate","indication":"Other","status":"marketed"},{"name":"Acular, Xibrom","genericName":"Acular, Xibrom","slug":"acular-xibrom","indication":"Other","status":"marketed"},{"name":"Bimatoprost 0.03%, Travoprost 0.004%","genericName":"Bimatoprost 0.03%, Travoprost 0.004%","slug":"bimatoprost-0-03-travoprost-0-004","indication":"Other","status":"marketed"},{"name":"Endura","genericName":"Endura","slug":"endura","indication":"Other","status":"marketed"},{"name":"Refresh Tears, 9582X","genericName":"Refresh Tears, 9582X","slug":"refresh-tears-9582x","indication":"Other","status":"marketed"},{"name":"Viscoat","genericName":"Viscoat","slug":"viscoat","indication":"Other","status":"marketed"},{"name":"ketorolac 0.4%, bromfenac 0.09%","genericName":"ketorolac 0.4%, bromfenac 0.09%","slug":"ketorolac-0-4-bromfenac-0-09","indication":"Other","status":"marketed"}]},{"name":"Ophthalmology","slug":"ophthalmology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Propylene Glycol 0.3%","genericName":"Propylene Glycol 0.3%","slug":"propylene-glycol-0-3","indication":"Eye Irritation Relief","status":"marketed"}]}],"pipeline":[{"name":"1. Optive","genericName":"1. Optive","slug":"1-optive","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Dermatix Q","genericName":"Dermatix Q","slug":"dermatix-q","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Bimatoprost 0.03%, Latanoprost","genericName":"Bimatoprost 0.03%, Latanoprost","slug":"bimatoprost-0-03-latanoprost","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Brimonidine Purite 0.15%, Dorzolamide 2%, Latanoprost","genericName":"Brimonidine Purite 0.15%, Dorzolamide 2%, Latanoprost","slug":"brimonidine-purite-0-15-dorzolamide-2-latanoprost","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"FreshKote","genericName":"FreshKote","slug":"freshkote","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Gatifloxacin 0.3%","genericName":"Gatifloxacin 0.3%","slug":"gatifloxacin-0-3","phase":"marketed","mechanism":"DNA gyrase and topoisomerase IV","indications":[],"catalyst":""},{"name":"Ketorolac, Nepafenac","genericName":"Ketorolac, Nepafenac","slug":"ketorolac-nepafenac","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Propylene Glycol 0.3%","genericName":"Propylene Glycol 0.3%","slug":"propylene-glycol-0-3","phase":"marketed","mechanism":"Small molecule","indications":["Eye Irritation Relief","Minor Eye Discomfort Relief"],"catalyst":""},{"name":"Systane","genericName":"Systane","slug":"systane","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"0.15% sodium Hyaluronate","genericName":"0.15% sodium Hyaluronate","slug":"0-15-sodium-hyaluronate","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Acular, Xibrom","genericName":"Acular, Xibrom","slug":"acular-xibrom","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Bimatoprost 0.03%, Travoprost 0.004%","genericName":"Bimatoprost 0.03%, Travoprost 0.004%","slug":"bimatoprost-0-03-travoprost-0-004","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Endura","genericName":"Endura","slug":"endura","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Refresh Tears, 9582X","genericName":"Refresh Tears, 9582X","slug":"refresh-tears-9582x","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Viscoat","genericName":"Viscoat","slug":"viscoat","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ketorolac 0.4%, bromfenac 0.09%","genericName":"ketorolac 0.4%, bromfenac 0.09%","slug":"ketorolac-0-4-bromfenac-0-09","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi1AFBVV95cUxOMllCUXhITjM5NWhCc2IyTy0wcV9xazJVQU9OZHI1S1dxLWNoQTF2em91NmczWlNVWk9qS01RZnZNTVJ1aTRyUW1HbDhzbTZETnRCUTRMRmh1RXpRZ3AwMzhGUXBtd2gwRVNSbC1Xc0ZXY0o2VWJlMnZGUGotLXVaemQ5ckR1eUpieTBqNm15VDFvX2lDZDRUNlA3OHo1Z3VjUmlOOGVZQUVvYk9saVBJNEZiZzNCMTdRdjNWSkNmOXNENWdScmFxR0R5a0tsWUpuQjZPQQ?oc=5","date":"2026-04-02","type":"regulatory","source":"GOV.UK","summary":"UK and US deepen regulatory cooperation on medical devices, building on wider pharmaceutical partnership - GOV.UK","headline":"UK and US deepen regulatory cooperation on medical devices, building on wider pharmaceutical partnership","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxNUFExZC0tNU1iT09JQWdGRXZVTWszUkpFbGJfNDJ6RG1xelFmdF95Q1g0U0tkR1pqdkNXVHdTYlFKS2VGV3NVWlRHaVpMa3VIaXUzZGN4Wl9DMWR2Z3cyN09mVGREMmxjU0NZYlAxajE4WlJ1WFlMMEhKWWRyRmtUWm51RVVsWXNaVld3bkt2TzBDaUZCTjF6cElxZTJNVFlTTkRwUkY4MUpQUQ?oc=5","date":"2026-03-24","type":"pipeline","source":"Fast Company","summary":"The most innovative medicine, therapeutics, and pharmaceutical companies of 2026 - Fast Company","headline":"The most innovative medicine, therapeutics, and pharmaceutical companies of 2026","sentiment":"neutral"},{"date":"2026-03-17","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2026-03-17","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-02-20","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-12-15","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2025-12-15","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-11-19","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-11-06","type":"earnings","source":"outlookbusiness.com","summary":"Sun Pharma Q2 Earnings: Innovative Medicine Sales Surpass Generics, Here’s What You Need to Know - outlookbusiness.com","headline":"Sun Pharma Q2 Earnings: Innovative Medicine Sales Surpass Generics, Here’s What You Need to Know","sentiment":"neutral"},{"date":"2025-10-29","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2025-10-29","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAJBVV95cUxObjMxZkxidmdjR0kwT21pTHFxQVMtemg2eXU0V0hhR1N1OEgwNjFWMkxKTG9RZFVueWluNVBOOXlnWkNoWU56dDktRF9pRC1zWGoxckgycy1QQlhJRDdGUkxoSlNrY2VEcDByNWNfY0UzblBwNUdVZWZlR25xSjJOaG9xUUVuN3hLam13Q1RzSDRITFFUeWpWQWQ2RVBJMmQ3Y1NMSzRzZWxJUkZPMzBtUF9ZSGY1SF9wWW9iWGlYRXk0cG9zSlQyNnBvN3ZWZ3RydFE1ZFVsWjljRFJqYjBQcjgycjA1ZjRLdlI5OW9nUzB6RER2WkkzWlhsZDFGNkwtNGhUUUotdTZOMWh2azBEMWhEalhwaVRhaDlaT3ZpUEdIOF9TMEMzVDRoSkE?oc=5","date":"2025-09-30","type":"pipeline","source":"PR Newswire","summary":"RA Capital Management Funds Expansion of ARS Pharma Commercial Activity, Expands Portfolio of Financing Solutions for Innovative Healthcare Companies - PR Newswire","headline":"RA Capital Management Funds Expansion of ARS Pharma Commercial Activity, Expands Portfolio of Financing Solutions for In","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxNNFVBb3lfZzZNa0toR21ONGtMeGdqU216blZsbl9qUzI1MTN4Y3pxSzFSSlBpSllKX1cyZ2hVajhEUnlWcmZsczFOMEpoZ0JMcGVCczhPNmFwTWhyTkc5MzdSSzMzMktETXRDTkF6YXNWUXlIZTUxdWh6MHhCdURKUTQ1ZGNRTnVBaDBrcEJWM3dsNkZJRDFhLVNwZDVZRWIweDFBcV9OeThkcUJhdEszMHc5eTByZ2EyWUlTVVV6eUs?oc=5","date":"2025-09-10","type":"regulatory","source":"Fierce Pharma","summary":"J&J's 'practice-changing' bladder cancer therapy Inlexzo lands FDA nod - Fierce Pharma","headline":"J&J's 'practice-changing' bladder cancer therapy Inlexzo lands FDA nod","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxNUEZRYVZBdV9OOXgxUGFXa01GRUJWNHpBdHFhOFREYjVtOFRTUGZLbXlMRFVnZ3gwR0V3UmdlVG0wMnhweWZOQjBsdHhndHNCVk1kNW43eGVjN1I3cGViVzZGemNhZ25Ua3FSTk1CM0h4N29zanJfZUIyVXpQdjBtdVdzbm9sTGNZYWVMQlN0d3FFNWJmd3M0dXVRZTR2SzVlNXl1bnJjclUwWUg0WDh2UGRWUUNHU0phRjlLTDFrZ3lqRVU?oc=5","date":"2025-08-28","type":"pipeline","source":"Pharmafile","summary":"The Pharma Files: With Professor Hatim Abdulhussein from Health Innovation Kent Surrey Sussex - Pharmafile","headline":"The Pharma Files: With Professor Hatim Abdulhussein from Health Innovation Kent Surrey Sussex","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2AFBVV95cUxQeXNsdlF4OGM4NkhUNUFwNVdPQlR3emhMVzJrVk1OVWY5YjVNSUdXZ1RYN0lQSTJ1bWdQaHBIQmVZOXVHX2FPR2lWVzM3dUpiT3ZkeGp6dGhfNEZ2Q25ibUZrQU5DVVRiMWJfcW5sLUJ5VHk4aDRoVGlyd3AxUjQyZm5xa0tqOHpEZkNiV24zbzUtbGc5RnFNSEoxVlZtTzJ1RVB6UVZpcnNOZnJNLXF3LXVlM0hyMlRqRnJwMkhfSFg5bHVDZi00T1BUb0kwMjJ2TkJUTHA2NXc?oc=5","date":"2025-08-11","type":"deal","source":"BioPharma APAC","summary":"AXA Partners with Hainan Boao Lecheng to Pioneer Innovative Cross-Border Medical Insurance Models - BioPharma APAC","headline":"AXA Partners with Hainan Boao Lecheng to Pioneer Innovative Cross-Border Medical Insurance Models","sentiment":"neutral"}],"patents":[],"drugCount":16,"phaseCounts":{"marketed":16},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":2198000,"revenuePeriod":"2025-07-31","revenueHistory":[{"value":2198000,"period":"2025-07-31"},{"value":1955000,"period":"2024-07-31"},{"value":1955000,"period":"2024-07-31"},{"value":1871000,"period":"2023-07-31"},{"value":1871000,"period":"2023-07-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":316000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-2399000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":1058000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}